Geron (GERN) 12th Annual Cantor Fitzgerald Global Healthcare Conference summary

Commercial performance and financial outlook

• Achieved 24% revenue growth in the first half of the year, with operating expenses reduced by 4%.

• Net revenue guidance for the year raised to the mid to high end of $230–$240 million.

• Three consecutive quarters of revenue growth, with Q2 net revenue at $57.5 million.

• Company is close to profitability, with operating expenses and revenue guidance aligned at $230–$240 million.

• Over $327 million in cash reserves, supporting both current operations and future growth initiatives.

Market strategy and growth drivers

• Focus shifting from academic medical centers to high-volume community centers for deeper market penetration.

• Emphasis on increasing use in second-line patients, supported by updated NCCN guidelines.

• Over a third of patients now come from earlier lines of therapy, with ongoing reporting on this shift.

• Gross-to-net discount guidance remains in the mid-20% range, with future adjustments possible as volume grows.

International expansion and ex-U.S. opportunities

• Global rights for the lead asset, with EMA approval and strong clinical trial presence in Europe.

• Exploring various go-to-market models in Europe, including partnerships and contract sales organizations, with an update expected by year-end.

• Ex-U.S. markets, including Europe, China, Japan, and others, represent significant growth potential.

• Ex-U.S. contribution in similar therapies has been substantial, with $500 million out of $2.5 billion in sales for a comparable product.